In January, the Cure JM Clinical Care Network was pleased to invite juvenile dermatomyositis healthcare professionals to join us virtually for the latest presentations from world-leading researchers and clinicians on advancements in basic research, translational studies, and best-practice clinical care in juvenile dermatomyositis.
Second-line treatments refer to options beyond steroids and methotrexate. They are designed to manage JM while reducing reliance on those medications. We understand that adding new treatments to your child’s regimen can be intimidating. However, rest assured that your doctor has carefully considered the benefits and risks of each option to design the best treatment plan for your family.
We recommend that mental health assessment and treatment options be an integral part of comprehensive care for children, adolescents, and adults with juvenile myositis.
Membership is free and we’ll connect you with a network of support, encouragement, and resources.
To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.
